


Supplemental Figure 1



Comparison of Plasma Surrogate Neutralizing Capacity (Percent ACE2 Inhibition) Between SOTR Fourth Recipients and HC third dose recipients. Inhibition of full-length SARS-CoV-2 spike variants (indicated in top header of each panel) was compared between SOTRs post-fourth dose (blue) and HCs post-third dose (red). The boxplots represent the IQR. The median is represented by a solid horizontal line in the box. The lower and upper whiskers represent 1.5x the IQR beyond the quartiles. Each dot represents an individual sample. Statistical differences between measurements were determined by Wilcoxon-Mann-Whitney test. Values of $p < 0.05$ were considered significant (***) indicates $p < 0.001$, ns indicates $p > 0.05$).

Supplemental Table 1.

Healthy control demographic information

Factor		Value
N		24
Male		11/24 (45.8%)
Age (years) ^a		
	21-30	6 (25%)
	31-40	6 (25%)
	41-50	7 (29%)
	51-60	5 (21%)
Vaccine (brand)	Moderna	1 (4%)
	Pfizer ^b	23 (96%)
Days after third dose	Median (IQR)	14 (13.75 – 16.25)

a. Only decade was provided by healthy control participants.

b. One participant received 2 doses of Pfizer followed by a third dose of Moderna.